Skip to content

Ketamine Psychedelic and Antinociceptive Effects Are Connected

Erik Olofsen, Jasper Kamp, Thomas K. Henthorn, Monique van Velzen, Marieke Niesters, Elise Sarton, Albert Dahan

Anesthesiology February 21, 2022 DOI: 10.1097/aln.0000000000004176 (opens in new tab)

The journal has published a correction to this paper. Read the correction (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Post hoc analysis of a pharmacokinetic-pharmacodynamic study Peer reviewed
Sample size 17
Population Healthy male volunteers
Interventions S-ketamine racemic ketamine
Dose escalating doses
Topics Ketamine Esketamine
Keywords Nociception Analgesic Morphine Hyperalgesia Anesthesia Pharmacology
Citations 33
Key points The pharmacodynamics of S-ketamine for antinociception and psychedelic symptoms were identical, supporting an association between ketamine analgesia and dissociation.

Abstract

Background: Ketamine produces potent analgesia combined with psychedelic effects. It has been suggested that these two effects are associated and possibly that analgesia is generated by ketamine-induced dissociation. The authors performed a post hoc analysis of previously published data to quantify the pharmacodynamic properties of ketamine-induced antinociception and psychedelic symptoms. The hypothesis was that ketamine pharmacodynamics (i.e., concentration-effect relationship as well as effect onset and offset times) are not different for these two endpoints.

Methods: Seventeen healthy male volunteers received escalating doses of S- and racemic ketamine on separate occasions. Before, during, and after ketamine infusion, changes in external perception were measured together with pain pressure threshold. A population pharmacokinetic-pharmacodynamic analysis was performed that took S- and R-ketamine and S- and R-norketamine plasma concentrations into account.

Results: The pharmacodynamics of S-ketamine did not differ for antinociception and external perception with potency parameter (median [95% CI]) C50, 0.51 (0.38 to 0.66) nmol/ml; blood-effect site equilibration half-life, 8.3 [5.1 to 13.0] min), irrespective of administration form (racemic ketamine or S-ketamine). R-ketamine did not contribute to either endpoint. For both endpoints, S-norketamine had a small antagonistic effect.

Conclusions: The authors conclude that their data support an association or connectivity between ketamine analgesia and dissociation. Given the intricacies of the study related to the pain model, measurement of dissociation, and complex modeling of the combination of ketamine and norketamine, it is the opinion of the authors that further studies are needed to detect functional connectivity between brain areas that produce the different ketamine effects.

Comparable studies

Other experimental studies on ketamine, most cited first.

Study Year Design Participants
Ketamine activates psychosis and alters limbic blood flow in schizophrenia Schizophrenic individuals 1995 Experimental study
The spectral exponent of the resting EEG indexes the presence of consciousness during unresponsiveness induced by propofol, xenon, and ketamine Healthy participants 2019 Controlled experimental study n = 15
Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation Normal human subjects 2003 Experimental study n = 7
Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans Human participants 2015 Experimental study
S(+)-ketamine Effect on Experimental Pain and Cardiac Output Healthy adult volunteers (10 men and 10 women) 2009 Pharmacokinetic-pharmacodynamic modeling study in healthy volunteers n = 20

Citations in the library

Explore topics